Furthermore, β-catenin/TCF complex target genes (ZEB1, CyclinD1 and c-Myc,) which were increased by doxorubicin, were downregulated following the disruption of β-catenin/TCF4 interaction in HCC cells (Fig. 4B). The gene discussed is CCND1; the disease is hepatocellular carcinoma.